Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease - 04/08/21
Key words : Aspirin-exacerbated respiratory disease, respiratory biologic, IgE, IL-5Rα, IL-4Rα, nasal polyp, mepolizumab, benralizumab, omalizumab, dupilumab
Le texte complet de cet article est disponible en PDF.
Plan
Supported by the National Institutes of Health (grants U19AI095219, K23AI139352, and R01HL128241) and by generous contributions from the Vinik and Kaye families. |
|
Disclosure of potential conflicts of interest: T. Laidlaw has served on scientific advisory boards for GlaxoSmithKline, Sanofi-Genzyme, Optinose, AstraZeneca, and Regeneron. K. Buchheit has served on scientific advisory boards for AstraZeneca and GlaxoSmithKline. J. Levy has served on scientific advisory boards for Regeneron Pharmaceuticals and GlaxoSmithKline. |
Vol 148 - N° 2
P. 348-350 - août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?